retatrutide triple agonist weight loss Retatrutide, a agonist, delivered 30.3% at two years in Phase 3. The headlines state: → 70 lbs average loss on 12mg at 80 weeks (28.3% of body weight) → 🚨 Retatrutide TRIUMPH-1 Phase 3

In this case, Theophyline inhibits Phosphodietrase

Get your weight down to a science Partner with a clinician to discuss your weight goals and complete testing to determine if GLP-1 medication is right for you

Rotate injection sites regularly to prevent lipodystrophy and scarring that can affect absorption

17 Conversely, findings from another population-based study suggested there was no overall increased risk of DR associated with GLP-1RA use, while a meta-analysis indicated albiglutide, a GLP-1RA no longer commercially available due to limited prescribing, was associated with an increased risk of early worsening (the four GLP-1RAs available did not exhibit a statistically significant association with DR)

GLP-1 agonists can also lead to nutrient deficiencies and hormone imbalances through malnutrition